Modality
Fusion Protein
MOA
EGFRi
Target
Cl18.2
Pathway
JAK/STAT
ADHDMCC
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Oct 2030
Phase 2Current
NCT07056863
1,526 pts·MCC
2023-05→2030-10·Terminated
NCT04211699
978 pts·ADHD
2017-01→2027-09·Active
2,504 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-231.5y awayPh3 Readout· ADHD
2030-10-264.6y awayPh3 Readout· MCC
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2027-09-23 · 1.5y away
ADHD
Ph3 Readout
2030-10-26 · 4.6y away
MCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07056863 | Phase 2/3 | MCC | Terminated | 1526 | PASI75 |
| NCT04211699 | Phase 2/3 | ADHD | Active | 978 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 |